Pharmacology and clinical applications of human recombinant antithrombin

Bibliography

• Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989;87:34S-8S
   PubMed Web of Science ®Google Scholar
• Lechner K, Kyrle PA. Antithrombin III concentrates – are they clinically useful? Thromb Haemost 1995;73:340-8
   PubMed Web of Science ®Google Scholar
• Buller HR, ten Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med 1989;87:44S-8S
   PubMed Web of Science ®Google Scholar
• Mammen EF. Clinical relevance of antithrombin deficiencies. Semin Hematol 1995;32(4 Suppl 2):2-6; discussion 7
   PubMed Web of Science ®Google Scholar
• Baker WF Jr, Bick RL. Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 1999;25:387-406
   PubMed Web of Science ®Google Scholar
• De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-44
   PubMed Web of Science ®Google Scholar
• Vinazzer H. Hereditary and acquired antithrombin deficiency. Semin Thromb Hemost 1999;25:257-63
   PubMed Web of Science ®Google Scholar
• Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975;292:146-51
   PubMed Web of Science ®Google Scholar
• Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007;67:1429-40
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008;14:1229-39
   PubMed Web of Science ®Google Scholar
• Edmunds T, Van Patten SM, Pollock J, Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998;91:4561-71
   PubMed Web of Science ®Google Scholar
• Peterson CB, Blackburn MN. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem 1985;260:610-15
   PubMed Web of Science ®Google Scholar
• Olson ST, Frances-Chmura AM, Swanson R, Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. Arch Biochem Biophys 1997;341:212-21
   PubMed Web of Science ®Google Scholar
• Franzen LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. J Biol Chem 1980;255:5090-3
   PubMed Web of Science ®Google Scholar
• Zhou Q, Kyazike J, Echelard Y, Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of transgenic goats. J Biotechnol 2005;117:57-72
   PubMed Web of Science ®Google Scholar
• Levy JH, Weisinger A, Ziomek CA, Echelard Y. Recombinant antithrombin: production and role in cardiovascular disorder. Semin Thromb Hemost 2001;27:405-16
   PubMed Web of Science ®Google Scholar
• Murano G, Williams L, Miller-Andersson M, Some properties of antithrombin-III and its concentration in human plasma. Thromb Res 1980;18:259-62
   PubMed Web of Science ®Google Scholar
• Pratt CW, Church FC. Antithrombin: structure and function. Semin Hematol 1991;28:3-9
   PubMed Web of Science ®Google Scholar
• Menache D, Grossman BJ, Jackson CM. Antithrombin III: physiology, deficiency, and replacement therapy. Transfusion 1992;32:580-8
   PubMed Web of Science ®Google Scholar
• Menache D. Antithrombin III: introduction. Semin Hematol 1991;28:1-2
   PubMed Web of Science ®Google Scholar
• Lahiri B, Bagdasarian A, Mitchell B, Antithrombin-heparin cofactor: an inhibitor of plasma kallikrein. Arch Biochem Biophys 1976;175:737-47
   PubMed Web of Science ®Google Scholar
• Rosenberg RD, Bauer KA, Marcum JA. Antithrombin III: The heparin-antithrombin system. In: Murano G, editor, Reviews of hematology: protease inhibitors of human plasma biochemistry and pathophysiology target. PJD Publications Ltd, Westbury, New York; 1986. p. 351-416
   Google Scholar
• Andersson LO, Engman L, Henningsson E. Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III–thrombin complex. J Immunol Methods 1977;14:271-81
   PubMed Web of Science ®Google Scholar
• Pizzo SV. Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med 1989;87(3B):10S-4S
   PubMed Web of Science ®Google Scholar
• Lane DA, Mannucci PM, Bauer KA, Inherited thrombophilia: part 1. Thromb Haemost 1996;76:651-62
   PubMed Web of Science ®Google Scholar
• Ersdal-Badju E, Lu A, Peng X, Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells. Biochem J 1995;310:323-30
   PubMed Web of Science ®Google Scholar
• Leitner JM, Firbas C, Mayr FB, Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther 2006;79:23-34
   PubMed Web of Science ®Google Scholar
• Kaneider NC, Forster E, Mosheimer B, Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 2003;90:1150-7
   PubMed Web of Science ®Google Scholar
• Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 1998;24:27-32
   PubMed Web of Science ®Google Scholar
• Neviere R, Tournoys A, Mordon S, Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock 2001;15:220-5
   PubMed Web of Science ®Google Scholar
• Sorg H, Hoffmann JN, Rumbaut RE, Efficacy of antithrombin in the prevention of microvascular thrombosis during endotoxemia: an intravital microscopic study. Thromb Res 2007;121:241-8
   PubMed Web of Science ®Google Scholar
• Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001;287:42-6
   PubMed Web of Science ®Google Scholar
• Lorant DE, Topham MK, Whatley RE, Inflammatory roles of P-selectin. J Clin Invest 1993;92:559-70
   PubMed Web of Science ®Google Scholar
• Ueno A, Murakami K, Yamanouchi K, Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. Immunology 1996;88:76-81
   PubMed Web of Science ®Google Scholar
• Sower LE, Froelich CJ, Carney DH, Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 1995;155:895-901
   PubMed Web of Science ®Google Scholar
• Ostrovsky L, Woodman RC, Payne D, Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997;96:2302-10
   PubMed Web of Science ®Google Scholar
• Senden NH, Jeunhomme TM, Heemskerk JW, Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998;161:4318-24
   PubMed Web of Science ®Google Scholar
• Feistritzer C, Wiedermann CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 2007;7:855-70
   PubMed Web of Science ®Google Scholar
• Gritti D, Malinverno A, Gasparetto C, Attenuation of leukocyte beta 2-integrin expression by antithrombin-III. Int J Immunopathol Pharmacol 2004;17:27-32
   PubMed Web of Science ®Google Scholar
• Lu W, Mant T, Levy JH, Bailey JM. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg 2000;90:531-4
   PubMed Web of Science ®Google Scholar
• Levy JH, Despotis GJ, Szlam F, Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002;96:1095-102
   PubMed Web of Science ®Google Scholar
• Knot EA, de Jong E, ten Cate JW, Antithrombin III: biodistribution in healthy volunteers. Thromb Haemost 1987;58:1008-11
   PubMed Web of Science ®Google Scholar
• de Swart CA, Nijmeyer B, Andersson LO, Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans. Thromb Haemost 1984;52:66-70
   PubMed Web of Science ®Google Scholar
• Collen D, Schetz J, de Cock F, Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest 1977;7:27-35
   PubMed Web of Science ®Google Scholar
• Konkle BA, Bauer KA, Weinstein R, Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003;43:390-4
   PubMed Web of Science ®Google Scholar
• Menache D, O'Malley JP, Schorr JB, Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990;75:33-9
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Bauer KA, Rosenberg RD, Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 1989;87(3B):53S-60S
   PubMed Web of Science ®Google Scholar
• Tiede A, Tait RC, Shaffer DW, Antithrombin alfa in hereditary antithrombin deficient patients: a phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost 2008;99:616-22
   PubMed Web of Science ®Google Scholar
• Frieling JT, Drenth H, Bonfiglio J, Pregnant hereditary antithrombin deeficieint women require a distinct dosing startegy for the management of AT activity levels with antithrombin alfa. J Thromb Haemost 2007;5(Suppl 2):P-M-479
   Google Scholar
• Buchanan GS, Rodgers GM, Ware Branch D. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. Best Pract Res Clin Obstet Gynaecol 2003;17:397-411
   PubMed Web of Science ®Google Scholar
• Walker ID, Greaves M, Preston E. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512-28
   PubMed Web of Science ®Google Scholar
• Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost 2005;3:1603-10
   PubMed Web of Science ®Google Scholar
• Walker ID. Management of thrombophilia in pregnancy. Blood Rev 1991;5:227-33
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119(Suppl 1):122S-31S
   PubMed Web of Science ®Google Scholar
• Bauer KA. Management of thrombophilia. J Thromb Haemost 2003;1:1429-34
   PubMed Web of Science ®Google Scholar
• Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992;68:634-6
   PubMed Web of Science ®Google Scholar
• Bucur SZ, Levy JH, Despotis GJ, Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998;38:481-98
   PubMed Web of Science ®Google Scholar
• Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004;30:1032-40
   PubMed Web of Science ®Google Scholar
• Schoots IG, Levi M, van Vliet AK, Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 2004;32:1375-83
   PubMed Web of Science ®Google Scholar
• Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med 2003;31:1108-12
   PubMed Web of Science ®Google Scholar
• Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 2001;16:167-77
   PubMed Web of Science ®Google Scholar
• Wada H. Disseminated intravascular coagulation. Clin Chim Acta 2004;344:13-21
   PubMed Web of Science ®Google Scholar
• Warren BL, Eid A, Singer P, Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78
   PubMed Web of Science ®Google Scholar
• Fourrier F, Chopin C, Huart JJ, Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-8
   PubMed Web of Science ®Google Scholar
• Inthorn D, Hoffmann JN, Hartl WH, Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997;8:328-34
   PubMed Web of Science ®Google Scholar
• Eisele B, Lamy M, Thijs LG, Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-72
   PubMed Web of Science ®Google Scholar
• Hoffmann JN, Wiedermann CJ, Juers M, Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006;95:850-6
   PubMed Web of Science ®Google Scholar
• Eid A, Wiedermann CJ, Kinasewitz GT. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial. Anesth Analg 2008;107:1633-8
   PubMed Web of Science ®Google Scholar
• Hoffmann JN, Muhlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004;32:1851-9
   PubMed Web of Science ®Google Scholar
• van Veen SQ, Cheung CW, Meijers JC, Anticoagulant and anti-inflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis. J Thromb Haemost 2006;4:2343-51
   PubMed Web of Science ®Google Scholar
• Hofstra JJ, Vlaar AP, Cornet AD, Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 2010;23:105-11
   PubMed Web of Science ®Google Scholar
• Zhang W, Chuang YJ, Jin Tet, Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res 2006;66:5047-55
   PubMed Web of Science ®Google Scholar
• Zhang W, Chuang YJ, Swanson R, Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004;103:1185-91
   PubMed Web of Science ®Google Scholar
• Zhang W, Swanson R, Izaguirre G, The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005;106:1621-8
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8
   PubMed Web of Science ®Google Scholar
• Larsson H, Akerud P, Nordling K, A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J Biol Chem 2001;276:11996-2002
   PubMed Web of Science ®Google Scholar
• Larsson H, Sjoblom T, Dixelius J, Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000;60:6723-9
   PubMed Web of Science ®Google Scholar
• Onizuka S, Kawakami S, Taniguchi K, Pancreatic carcinogenesis: apoptosis and angiogenesis. Pancreas 2004;28:317-19
   PubMed Web of Science ®Google Scholar
• Prox D, Becker C, Pirie-Shepherd SR, Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 2003;27:405-11
   PubMed Web of Science ®Google Scholar
• Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001;15:311-20
   PubMed Web of Science ®Google Scholar
• Geiben-Lynn R, Brown N, Walker BD, Luster AD. Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J Biol Chem 2002;277:42352-7
   PubMed Web of Science ®Google Scholar
• Elmaleh DR, Brown NV, Geiben-Lynn R. Anti-viral activity of human antithrombin III. Int J Mol Med 2005;16:191-200
   PubMed Web of Science ®Google Scholar
• Hoffmann JN, Fertmann JM, Jauch KW. Microcirculatory disorders in sepsis and transplantation: therapy with natural coagulatory inhibitors antithrombin and activated protein C. Curr Opin Crit Care 2006;12:426-30
   PubMed Web of Science ®Google Scholar
• Ozden A, Sarioglu A, Demirkan NC, Antithrombin III reduces renal ischemia-reperfusion injury in rats. Res Exp Med (Berl) 2001;200(3):195-203
   PubMedGoogle Scholar
• Harada N, Okajima K, Kushimoto S, Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999;93:157-64
   PubMed Web of Science ®Google Scholar
• Arakami O, Takayama T, Yokoyama T, High dose of antithrombin III induces indefinite survival of fully allogenic cardiac grafts and generates regulatory cells. Transplantation 2003;75:217-20
   PubMed Web of Science ®Google Scholar
• Hoffmann JN, Arbogast HP, Fertmann J, High dose antithrombin therapy reduces ischemia/reperfusion injury during human allogenic kidney transplantation: first results of a randomized controlled clinical trial. Transplantation (Abstract Issue, TTS Meeting, Miami) 2002;74:394-5
   Google Scholar
• Cowan PJ, Aminian A, Barlow H, Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002;2:520-5
   PubMed Web of Science ®Google Scholar
• Fertmann JM, Wimmer CD, Arbogast HP, Single-shot antithrombin in human pancreas-kidney transplantation: reduction of reperfusion pancreatitis and prevention of graft thrombosis. Transpl Int 2006;19:458-65
   PubMed Web of Science ®Google Scholar
• Langley PG, Hughes RD, Forbes A, Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol 1993;17:326-31
   PubMed Web of Science ®Google Scholar
• Despotis GJ. Heparin resistance and the potential impact on maintenance of therapeautic coagulation. Eur J Anaesthesiol 2007;24(Suppl 40):37-58
   Google Scholar
• Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993;23(Suppl 1):103-6
   PubMedGoogle Scholar
• Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991;64:155-68
   PubMed Web of Science ®Google Scholar
• Sobel M, McNeill PM, Carlson PL, Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87(5):1787-93
   PubMed Web of Science ®Google Scholar
• Khuri SF, Valeri CR, Loscalzo J, Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-14
   PubMed Web of Science ®Google Scholar
• Koster A, Fischer T, Praus M, Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002;97:837-41
   PubMed Web of Science ®Google Scholar
• Avidan MS, Levy JH, Scholz J, A Phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005;102:276-84
   PubMed Web of Science ®Google Scholar
• Avidan MS, Levy JH, van Aken H, Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-13
   PubMed Web of Science ®Google Scholar
• Levy JH, Despotis GJ, Olson PJ, Transgenically produced recombinant human antithrombin III enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery. Blood 1997;90(Suppl I): abstract 298A
   Google Scholar
• Heindel SW, Mill MR, Freid EB, Fatal thrombosis associated with a hemi-fontan procedure, heparin-protamine reversal, and aprotinin. Anesthesiology 2001;94:369-71
   PubMed Web of Science ®Google Scholar
• Ranucci M, Frigiola A, Menicanti L, Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005;33:355-60
   PubMed Web of Science ®Google Scholar
• Sodeck GH, Schillinger M, Ehrlich MP, Preoperative antithrombin III activity predicts outcome after surgical repair of acute type A aortic dissection. Atherosclerosis 2006;186:107-12
   PubMed Web of Science ®Google Scholar
• Rossi M, Ranucci M, Soro G, Purified antithrombin supplementation in coronary revascularisation operations. Eur J Anaesthesiol 2007;24(Suppl 40):71-6
   PubMedGoogle Scholar
• Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thromb Haemost 2009;101(5):806-12
   PubMed Web of Science ®Google Scholar